Beltran, Pedro

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery

Cell death mechanisms and regulationAcute Myeloid Leukemia Research

Cited by 432

Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition

Crespo-Garcia, S., Tsuruda, P. R., Dejda, A., Ryan, R. D., Fournier, F., Chaney, S. Y., Pilon, F., Dogan, T., Cagnone, G., Patel, P., et al. (2021) · Cell Metabolism

Telomeres, Telomerase, and SenescenceRetinal Diseases and Treatments

Cited by 182

Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

Mao, K., Quipildor, G. F., Tabrizian, T., Novaj, A., Guan, F., Walters, R. O., Delahaye, F., Hubbard, G. B., Ikeno, Y., Ejima, K., et al. (2018) · Nature Communications

Genetics, Aging, and Longevity in Model OrganismsGrowth Hormone and Insulin-like Growth Factors

Cited by 167

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

Beltran, P., Dhirendra, S., Xu, R., Chen, M., Czyzyk, D., Donovan, S., Feng, S., Feng, C., Fu, L., Lightstone, F., et al. (2024) · Cancer Research

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 6